From early innovations to commercial triumphs: One viral vector partner for every stage of gene therapy development

Viral vector-based gene therapies hold promise for treating previously untreatable diseases like genetic disorders, rare cancers, and infectious diseases. However, developing and manufacturing these therapies involves significant challenges, including scaling up production, ensuring sterility, navigating regulatory requirements, and maintaining a reliable supply chain. Contract development and manufacturing organizations (CDMOs) like Thermo Fisher Scientific provide essential support, offering expertise, advanced facilities, and standardized processes from pre-clinical stages to commercial manufacturing. Read this article for an overview of how CDMOs can support gene therapy developers, with an emphasis on the following key points:

• Learn tailored viral vector production for diverse partner needs.
• Discover scalability through flexible production.
• Understand ongoing support across development stages.